ARS Pharmaceuticals, Inc., a pharmaceutical preparations company, has entered into a significant supply agreement with Nuova Ompi S.r.l., a Stevanato Group subsidiary. The agreement, effective October 8, 2024, ensures the supply of glass microvials for ARS Pharmaceuticals' neffy®, an emergency medication.
Under the terms of the contract, ARS Pharmaceuticals' subsidiary, ARS Pharmaceuticals Operations, Inc., has committed to purchase specified annual minimum quantities of the microvials. These amounts can be increased if ARS Pharmaceuticals gives prior notice or through a forecast process, with a set annual limit. Nuova Ompi S.r.l. is required to maintain the necessary manufacturing capabilities to meet its supply commitments.
In exchange for the supply arrangement, ARS Pharmaceuticals will make an upfront payment of three million Euros to the supplier. The agreement also stipulates the supply price for the microvials, which is subject to an annual adjustment. This adjustment is capped at a certain percentage, except in cases of substantial and exceptional increases in the supplier's production costs.
The supply agreement is set to last until December 31, 2035, but it can be terminated earlier by mutual consent, by ARS Pharmaceuticals for reasonable business reasons effective at the end of the following calendar year, or by either party if the other fails to remedy a material breach within 90 days of receiving notice.
This strategic partnership is critical for ARS Pharmaceuticals, ensuring a steady supply of essential components for their neffy® product line. The agreement reflects the company's commitment to securing long-term resources for its emergency medication offerings.
The information is based on a press release statement filed with the Securities and Exchange Commission.
In other recent news, ARS Pharmaceuticals has updated its manufacturing agreement with Renaissance Lakewood, LLC, extending the contract duration for the production of neffy nasal unit dose sprays. This development follows recent approvals of the company's products.
The FDA has greenlit neffy, a needle-free epinephrine treatment for Type I Allergic Reactions, now available by prescription across the United States. In addition, the European Commission has approved EURneffy, the first needle-free adrenaline nasal spray in the European Union, expected to be available in certain EU Member States by Q4 2024.
ARS Pharmaceuticals is also seeking FDA approval for neffy 1 mg, targeting younger children with severe allergies. This product aims to address the widespread fear of needles, often a barrier to treatment. Analyst firm Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with an Overweight rating, indicating a positive outlook for the company's potential.
InvestingPro Insights
ARS Pharmaceuticals' (SPRY) recent supply agreement aligns with its growth strategy, as reflected in the latest InvestingPro data. The company's revenue growth has been impressive, with a 128.31% increase in the last twelve months as of Q2 2024. This growth trajectory is further supported by an InvestingPro Tip indicating that analysts anticipate sales growth in the current year.
The long-term nature of the supply agreement until 2035 demonstrates ARS Pharmaceuticals' confidence in its future prospects. This is mirrored in the company's strong market performance, with InvestingPro data showing a 300.8% price total return over the past year. Another InvestingPro Tip highlights that the company holds more cash than debt on its balance sheet, suggesting financial stability to support such long-term commitments.
However, investors should note that despite the positive revenue growth, ARS Pharmaceuticals is not yet profitable, with a negative operating income of -56.74M USD in the last twelve months. An additional InvestingPro Tip warns that analysts do not anticipate the company will be profitable this year, which may explain the high revenue valuation multiple at which it's currently trading.
For readers interested in a more comprehensive analysis, InvestingPro offers 13 additional tips for ARS Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.